^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

Published date:
05/07/2021
Excerpt:
This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT01548144)....Out of 9 patients enrolled in this trial with either MET or ALK aberrations, one patient with colon cancer and ALK p.R1209Q mutation had a best response of PR (−33%)...
DOI:
10.2147/OTT.S291801
Trial ID: